Concepedia

Author

Brett Wallden

Nanostring Technologies (United States)

Also Known As

B Wallden, B. Wallden, Brett Wallden, Perou, Charles, Wallden, Brett

22

Publications

1.4K

Citations

9

H-Index

23

Concepts

All Affiliations

Nanostring Technologies (United States)University of WashingtonSeattle UniversityBC Cancer Agency
BW

About

Brett Wallden is an author at Nanostring Technologies (United States) specializing in tumor immunity, tumor biology, and pathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

431

2

Immunology

2

2

431

3

Pathology

2

2

431

4

Engineering

1

1

18

5

Molecular Biology

1

1

18

Brett Wallden

×

9

Publications

1.4K

Citations

9

H-Index

YearCitations

Development and verification of the PAM50-based Prosigna breast cancer gene signature assay

Brett Wallden, James J. Storhoff, Torsten O. Nielsen,

BMC Medical Genomics

2015

543

Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)

Patrick Danaher, Sarah Warren, Rongze Lu,

Journal for ImmunoTherapy of Cancer

2018

413

Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens

Torsten O. Nielsen, Brett Wallden, Carl Schaper,

BMC Cancer

2014

303

PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients

Charlotte L. Tykjaer Jørgensen, Torsten O. Nielsen, Karsten Bjerre,

Acta Oncologica

2013

32

Development and analytical performance of a molecular diagnostic for anti-PD1 response on the nCounter Dx Analysis System.

Brett Wallden, Irena Pekker, Simina Popa,

Journal of Clinical Oncology

2016

18

Truncated RAR beta isoform enhances proliferation and retinoid resistance

Mari E. Swift, Brett Wallden, Elizabeth A. Wayner,

Journal of Cellular Physiology

2006

16

Werner syndrome gene variants in human sarcomas

Jessica Hsu, Ashwini S. Kamath‐Loeb, Eitan Glick,

Molecular Carcinogenesis

2009

16

Antimetastatic gene expression profiles mediated by retinoic acid receptor beta 2 in MDA-MB-435 breast cancer cells

Brett Wallden, Mary J. Emond, Mari E. Swift,

BMC Cancer

2005

15

Development of the molecular diagnostic (MDx) DLBCL Lymphoma Subtyping Test (LST) on the nCounter Analysis System.

Brett Wallden, Sean Ferree, Harini Ravi,

Journal of Clinical Oncology

2015

10

Page 1